Nov. 7, 2018
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc., announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease, according to a press release issued by the two companies.
Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ optomap ultra-widefield retinal imaging devices to diagnose Alzheimer’s Disease in patients.
Through this alliance, Optos and Amydis will collaborate on the clinical development of Amydis’ test for the detection of Alzheimer’s disease. The partnership will combine Optos’ proprietary ultra-widefield
Other Articles to Explore
technology and strong commercial presence among eyecare specialists, with Amydis’ proprietary compounds to expand Optos’ market opportunity into the field of neurodegeneration.
These compounds bind to specific biomarkers in the retina and fluoresce making them visible with an optomap retinal camera. Together, Optos and Amydis say they will work to provide “an innovative medical solution to assist physicians and pharmaceutical companies discovering therapeutic interventions, and address the large unmet clinical need for early diagnosis of Alzheimer’s patients.”
“We are proud of the ongoing use of optomap imaging devices in clinical research to visualize biomarkers in the retina associated with Alzheimer’s Disease. This clinical collaboration with Amydis supports Optos’ vision to help physicians diagnose and monitor disease by studying the retina. We are pleased to work with Amydis in this important alliance and the benefit it may bring to patients suffering from Alzheimer’s Disease,” says Robert Kennedy, chief executive officer, Optos.
“We are very excited with the opportunity to use our targeted fluorescent probe technology with Optos’ ultra-widefield retinal cameras to develop a simple screening test to diagnose Alzheimer’s Disease,” says Stella Sarraf, PhD, chief executive Ooicer of Amydis.
